The primary research focus of Jin Jen, M.D., Ph.D., is the molecular genetics of non-small cell lung cancer. Dr. Jen is an expert in next-generation sequencing (NGS)-based technologies and in using this platform to identify tumor-associated molecular alterations for cancer detection, prognosis and treatment stratification.
Dr. Jen is co-director of the Genome Analysis Core of the Medical Genome Facility within the Center for Individualized Medicine (CIM) at Mayo Clinic. In this capacity, she leads the technology development operations and has enabled the optimization and implementation of NGS-based technologies for whole-transcriptome sequencing using a variety of sample types for research and clinical applications.
Dr. Jen is also member of the Biomarker Discovery Program in CIM. She collaborates closely with both basic and clinical scientists using state-of-the-art technologies for biomarker and bioassay discoveries and test development to improve the ability to assess lung cancer progression, treatment response and outcome.
- RNA sequencing for novel and rare gene fusions in cancer and their clinical implications
- Immune signatures and biomarkers in lung cancer progression and treatment stratification
- Circulating cell-free DNA for the detection, treatment monitoring and prognosis in lung cancer and other diseases
- Development and use of patient-derived tumor models to optimize treatment selection
- Novel methods and applications using NGS-based technologies for clinical test development
Significance to patient care
Cancer remains a deadly disease in many situations. However, increased understanding of cancer through comprehensive genome sequencing has greatly enhanced diagnoses, improved treatment selection, and extended survival for patients with cancer.
Dr. Jen's research and technology development expertise has led to the identification of novel and rare gene fusions in lung cancer as well as the establishment of genetic-based molecular assays for research discoveries and in clinical applications. The ongoing liquid biopsy-based study that she leads aims to enable a better understanding of the clinical significance in using circulating tumor DNA load to monitor lung cancer progression and outcome in patients with advanced stages of the disease.